Omega-3 fatty acids for cardioprotection

Lee, John H., O'Keefe, James H., Lavie, Carl J., Marchioli, Roberto and Harris, William S. (2008) Omega-3 fatty acids for cardioprotection. Mayo Clinic Proceedings, 83 3: 324-332. doi:10.4065/83.3.324

Author Lee, John H.
O'Keefe, James H.
Lavie, Carl J.
Marchioli, Roberto
Harris, William S.
Title Omega-3 fatty acids for cardioprotection
Journal name Mayo Clinic Proceedings   Check publisher's open access policy
ISSN 0025-6196
Publication date 2008-03
Sub-type Critical review of research, literature review, critical commentary
DOI 10.4065/83.3.324
Volume 83
Issue 3
Start page 324
End page 332
Total pages 9
Place of publication New York, United States
Publisher Elsevier
Language eng
Abstract The most compelling evidence for the cardiovascular benefit provided by omega-3 fatty acids comes from 3 large controlled trials of 32,000 participants randomized to receive omega-3 fatty acid supplements containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) or to act as controls. These trials showed reductions in cardiovascular events of 19% to 45%. These findings suggest that intake of omega-3 fatty acids, whether from dietary sources or fish oil supplements, should be increased, especially in those with or at risk for coronary artery disease. Patients should consume both DHA and EPA. The target DHA and EPA consumption levels are about 1 g/d for those with known coronary artery disease and at least 500 mg/d for those without disease. Patients with hypertriglyceridemia benefit from treatment with 3 to 4 g/d of DHA and EPA, a dosage that lowers triglyceride levels by 20% to 50%. Although 2 meals of oily fish per week can provide 400 to 500 mg/d of DHA and EPA, secondary prevention patients and those with hypertriglyceridemia must use fish oil supplements if they are to reach 1 g/d and 3 to 4 g/d of DHA and EPA, respectively. Combination therapy with omega-3 fatty acids and a statin is a safe and effective way to improve lipid levels and cardiovascular prognosis beyond the benefits provided by statin therapy alone. Blood DHA and EPA levels could one day be used to identify patients with deficient levels and to individualize therapeutic recommendations.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: ERA 2012 Admin Only
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 131 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 150 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 14 Mar 2011, 09:33:09 EST